Guido Baechler
CEO
Mainz Biomed
Mainz BioMed develops molecular genetic diagnostic solutions for at-home cancer detection, focusing on early identification of colorectal and pancreatic cancers. Their technology provides patients and healthcare providers with accessible and reliable testing options, aiming to improve survival rates through timely diagnosis.
- Biotechnology
- Digital Health
Updated 5 months ago
Funding
Raised to date
$8MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Colorectal and pancreatic cancers often go undetected until advanced stages, leading to lower survival rates. Traditional cancer detection methods can be invasive, inconvenient, and costly, resulting in delayed or avoided screenings. This lack of accessible and reliable early detection methods contributes to poorer patient outcomes.
Solution
Mainz BioMed develops and commercializes molecular genetic diagnostic solutions designed for the early detection of life-threatening cancers, including colorectal and pancreatic cancer. Their flagship product, ColoAlert, is a non-invasive, at-home diagnostic test that utilizes stool samples to detect colorectal cancer tumor DNA through polymerase chain reaction (PCR) technology. ColoAlert identifies genetic mutations associated with colorectal cancer and advanced adenomas, offering a convenient and accurate screening option. Mainz BioMed is also developing PancAlert, an early-stage pancreatic cancer screening test that uses real-time PCR-based multiplex detection of molecular-genetic biomarkers in stool samples.
Target Audience
The primary target audience includes patients at risk of colorectal cancer, healthcare providers seeking accessible and reliable screening options, and clinical laboratories.
Features
- Non-invasive, at-home sample collection
- ColoAlert utilizes PCR technology to detect colorectal cancer tumor DNA in stool samples
- Identifies genetic mutations associated with colorectal cancer and advanced adenomas
- ColoAlert is marketed across Europe and the United Arab Emirates
- Currently running a pivotal FDA clinical study for US regulatory approval of ColoAlert
- Developing PancAlert, an early-stage pancreatic cancer screening test
- PancAlert uses real-time PCR-based multiplex detection of molecular-genetic biomarkers in stool samples